Ferenc Gallyas Selected Research

2- ((2- piperidin- 1- ylethyl)thio)quinazolin- 4(3H)- one

1/2017	Chronic PARP-1 inhibition reduces carotid vessel remodeling and oxidative damage of the dorsal hippocampus in spontaneously hypertensive rats.
7/2014	A quinazoline-derivative compound with PARP inhibitory effect suppresses hypertension-induced vascular alterations in spontaneously hypertensive rats.
1/2014	PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1/GSK-3β and several PKC isoforms.
7/2006	PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ferenc Gallyas Research Topics

Disease

13	Neoplasms (Cancer) 01/2021 - 03/2002
10	Inflammation (Inflammations) 01/2021 - 07/2004
7	Necrosis 01/2017 - 05/2002
6	Hypertension (High Blood Pressure) 01/2021 - 01/2013
6	Ischemia 01/2013 - 04/2003
5	Multiple Sclerosis 01/2020 - 03/2010
4	Melanoma (Melanoma, Malignant) 01/2022 - 01/2019
4	Hypertrophy 01/2021 - 07/2006
4	Heart Failure 01/2021 - 07/2006
4	Demyelinating Diseases (Demyelinating Disease) 01/2020 - 03/2010
3	Triple Negative Breast Neoplasms 01/2022 - 02/2021
3	Disease Progression 01/2021 - 01/2017
3	Shock 01/2021 - 05/2002
3	Septic Shock (Toxic Shock Syndrome) 02/2009 - 04/2003
3	Retinal Degeneration 09/2007 - 07/2006
2	Breast Neoplasms (Breast Cancer) 08/2021 - 02/2021
2	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2017
2	Urinary Bladder Neoplasms (Bladder Cancer) 01/2017 - 01/2009
2	Vascular Remodeling 01/2017 - 07/2014
2	Cardiomegaly (Heart Hypertrophy) 06/2009 - 07/2006
2	Fibrosis (Cirrhosis) 06/2009 - 07/2006
2	Infarction (Infarctions) 09/2006 - 02/2006
1	Crohn Disease (Crohn's Disease) 01/2021
1	Colitis 01/2021
1	Sepsis (Septicemia) 01/2021
1	Endotoxemia 01/2021
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2021
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2020
1	Brain Ischemia (Cerebral Ischemia) 10/2019
1	Hypoxia (Hypoxemia) 01/2019
1	Retinal Diseases 01/2019
1	Autosomal Dominant Optic Atrophy (Dominant Optic Atrophy) 01/2018

Drug/Important Bio-Agent (IBA)

15	Poly(ADP-ribose) Polymerase InhibitorsIBA 02/2021 - 04/2003
11	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 02/2021 - 05/2002
8	Pharmaceutical PreparationsIBA 08/2021 - 07/2006
8	Phosphotransferases (Kinase)IBA 02/2020 - 07/2004
7	Cytostatic AgentsIBA 08/2021 - 01/2009
6	LipopolysaccharidesIBA 01/2021 - 05/2002
6	BGP 15IBA 01/2021 - 03/2002
6	EnzymesIBA 04/2020 - 05/2002
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 02/2006
5	desethylamiodaroneIBA 01/2022 - 11/2003
5	Amiodarone (Amiodarona)FDA LinkGeneric 01/2022 - 04/2003
4	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021 - 09/2006
4	CuprizoneIBA 01/2020 - 03/2010
4	N- (oxo- 5,6- dihydrophenanthridin- 2- yl)- N,N- dimethylacetamide hydrochlorideIBA 01/2019 - 05/2002
4	2- ((2- piperidin- 1- ylethyl)thio)quinazolin- 4(3H)- oneIBA 01/2017 - 07/2006
3	olaparibIBA 02/2021 - 01/2019
3	Poly (ADP-Ribose) Polymerase-1IBA 01/2021 - 07/2004
3	Adenosine Triphosphate (ATP)IBA 06/2012 - 10/2005
3	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 05/2012 - 04/2003
3	PolyphenolsIBA 01/2011 - 02/2009
3	Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)IBA 11/2010 - 07/2006
3	Sodium Glutamate (Accent)IBA 09/2007 - 07/2006
3	EndotoxinsIBA 07/2004 - 05/2002
2	2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- oneIBA 02/2021 - 02/2006
2	CollagenIBA 01/2021 - 07/2006
2	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 01/2021 - 01/2017
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021 - 05/2013
2	Cisplatin (Platino)FDA LinkGeneric 01/2019 - 03/2002
2	p38 Mitogen-Activated Protein KinasesIBA 01/2017 - 01/2014
2	Small Heat-Shock ProteinsIBA 01/2015 - 12/2007
2	Transcription Factors (Transcription Factor)IBA 07/2014 - 07/2004
2	NF-kappa B (NF-kB)IBA 07/2014 - 07/2004
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2014 - 01/2013
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2014 - 07/2006
2	CytokinesIBA 01/2014 - 11/2010
2	ChemokinesIBA 01/2014 - 11/2010
2	Phosphates (Orthophosphate)IBA 06/2012 - 04/2003
2	Mitogen-Activated Protein KinasesIBA 05/2012 - 07/2006
2	ferulaldehydeIBA 01/2011 - 02/2009
2	Apoptosis Inducing FactorIBA 03/2010 - 11/2003
2	Protein Kinase CIBA 06/2009 - 07/2006
2	Adenosine (Adenocard)FDA LinkGeneric 07/2006 - 05/2002
2	Glycogen Synthase Kinase 3 betaIBA 07/2006 - 02/2006
2	Carisoprodol (Soma)FDA LinkGeneric 06/2006 - 05/2004
2	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 02/2006 - 07/2004
1	Anti-Arrhythmia AgentsIBA 01/2022
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2022
1	nitroxylIBA 08/2021
1	pyrrolineIBA 08/2021
1	mito-carboxy proxylIBA 08/2021
1	Platinum Compounds (Compounds, Platinum)IBA 02/2021
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 02/2021
1	Hormones (Hormone)IBA 02/2021
1	Interleukin-10 (Interleukin 10)IBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021
1	Sulfonic AcidsIBA 01/2021
1	Cyclophilins (Cyclophilin)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	sym-trinitrobenzeneIBA 01/2021
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2021
1	Therapeutic UsesIBA 04/2020
1	Neuroprotective AgentsIBA 10/2019
1	vinpocetineIBA 10/2019
1	Retinaldehyde (Retinal)IBA 01/2019
1	Temozolomide (Temodar)FDA LinkGeneric 01/2019
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019

Therapy/Procedure

13	Therapeutics 08/2021 - 01/2009